Microbiota Antigen Compositions for Immune Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-mediated inflammatory diseases like Crohn's disease and ulcerative colitis are inadequate, as they do not effectively change the natural history of the diseases and lack reliable diagnostic and prognostic markers.
Innovation Solution
Development of compositions including polypeptides, polynucleotides, antibodies, and antigen-presenting cells that specifically target immunodominant antigens of the microbiota, which modulate immune reactivity and serve as diagnostic and therapeutic tools for immune-mediated inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for immune-mediated inflammatory diseases are used, then patients receive standard therapy, but the treatments do not effectively change the natural history of the diseases and lack reliable diagnostic and prognostic markers
Solution Approach 1:
The patent segments the complex immune-mediated inflammatory disease treatment into multiple distinct components: specific microbiota antigens (such as flagellin proteins), adjuvants, and optional immunomodulators. This segmentation allows each component to be optimized independently while working together to achieve effective treatment and diagnostic capabilities
Solution Approach 2:
The therapeutic compositions are designed with multi-functionality, serving both as diagnostic tools (through detection of immune responses to specific antigens) and as therapeutic agents (through modulation of immune reactivity). This universal approach addresses both the diagnostic marker deficiency and treatment effectiveness issues simultaneously
2Adaptability or versatility
If compositions targeting immunodominant antigens of the microbiota are developed, then novel therapies and diagnostic markers are provided, but the complexity of identifying and characterizing these antigens increases
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing immunodominant microbiota antigens (such as flagellin proteins CBir1, CBir3, FlaX) before clinical application. This advance characterization includes determining their immunogenic properties and establishing their presence in specific disease states, thereby creating ready-to-use diagnostic and therapeutic tools without requiring de novo identification during patient care
Solution Approach 2:
The patent uses the host immune response to microbiota antigens as an intermediary marker. Instead of directly measuring disease pathology, the compositions detect and measure immune responses (antibodies, T-cell reactions) to specific microbial antigens, which serve as intermediate indicators of disease state, prognosis, and treatment response
Data Source
AI summary
Compositions and methods for the therapy and diagnosis of immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis, are disclosed. Illustrative compositions comprise one or more bacterial polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention or treatment of immune-mediated inflammatory disease.